TULSA-PRO
Device
Incision-free transurethral ultrasound ablation system for prostate tissue, with 360-degree targeting and real-time MRI temperature monitoring.
Learn more
Mississauga-based commercial-stage medical device company making incision-free, MRI-guided ablation systems, including TULSA-PRO for prostate tissue and Sonalleve.

Canadian innovation builds a brighter tomorrow.
Profound Medical is a commercial-stage medical device company whose TULSA-PRO system performs transurethral ultrasound ablation of prostate tissue. The company describes it as an incision-free ablative intervention with customizable planning, 360-degree targeting, real-time MRI thermometry and closed-loop feedback, supported by 70 peer-reviewed publications through five-year outcomes. Its shares trade on both Nasdaq (PROF) and the TSX (PRN).
Reported Q2 2026 revenue of about $2.5M, up 12% year over year, and guided FY2026 total revenue of roughly $25.0M, or 56% growth. ir.profoundmedical.com
Launched a new Treatment Delivery Console software in August 2026, adding real-time interventional MRI control for TULSA-PRO. ir.profoundmedical.com
Appointed Richard Fabian, former CEO of FUJIFILM Sonosite, as President effective September 1, 2026, with Mathieu Burtnyk moving to a new CTO role. ir.profoundmedical.com
Dual listed: its investor site states the shares trade as NASDAQ: PROF and TSX: PRN, from 2400 Skymark Avenue, Mississauga. ir.profoundmedical.com
Products Profound Medical publishes on its own site. Each card links to the page it was taken from.
Device
Incision-free transurethral ultrasound ablation system for prostate tissue, with 360-degree targeting and real-time MRI temperature monitoring.
Learn moreDevice
MRI-guided focused ultrasound platform in the Profound Medical product line.
Learn moreTerms the company uses about its own work.
Other companies in Biotechnology & Life Sciences.
Discover companies, track funding, explore career opportunities and stay informed about Canada’s growing tech ecosystem.